Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

OBSRV: Observe Medical Announces Repeat Order for UnoMeter Safeti MAX Following Successful Customer Evaluation

OBSRVRegulatory press release30.09.2026 klo 15.42
Read the release
Oslo, 30 September 2026 - Observe Medical ASA (the "Company" or "Observe
Medical") today announces a repeat customer order for UnoMeter Safeti MAX,
following a comprehensive customer evaluation and successful testing of the
product and its unique, patented technology.

The repeat order follows the customer's thorough evaluation of UnoMeter Safeti
MAX in clinical use, including its innovative product features and the potential
clinical and health-economic benefits of the solution. Following the successful
evaluation, the customer has chosen to place a new order, providing an important
early commercial validation of both the product and the underlying patented
technology.

UnoMeter Safeti MAX represents an important innovation within urine measurement
and is designed to improve clinical workflow, patient safety and ease of use.
The product incorporates proprietary and patented technology, differentiating it
from traditional urine measurement solutions.

The repeat order represents an important milestone in the commercialization of
UnoMeter Safeti MAX. Observe Medical is experiencing good traction following the
product launch, with increasing customer interest and a growing pipeline of
commercial opportunities.

"We are very pleased to see a customer move from a thorough evaluation of
UnoMeter Safeti MAX to placing a repeat order. This is particularly important to
us, as the decision follows hands-on testing of the product and its unique
patented technology in a clinical setting. We see this as an encouraging early
validation of the value proposition and an important step in building recurring
commercial demand for UnoMeter Safeti MAX," said Jørgen Mann, CEO of Observe
Medical ASA.

With UnoMeter Safeti MAX successfully launched and now generating repeat orders
following customer evaluations, Observe Medical continues to focus on converting
its growing pipeline and customer interest into further commercial orders and
broader market adoption.

For further information, please contact:

Jørgen Mann, CEO Observe Medical
Mobile: +45 408 67 (http://tel:+45 408 67) 558
E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe Medical
Mobile: +47 958 12 (http://tel:+47 958 12) 765
E-mail: johan.fagerli@observemedical.com

About Observe Medical

Observe Medical is a Nordic medtech company that develops, markets and sells
innovative medtech products for the global market. The Company is committed to
improving patient welfare and patient outcomes, improving clinical data accuracy
and promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales and
commercialization of its broad portfolio of medical technology products, mainly
in urine measurement and ultrasound, in combination with targeted M&A and
distribution. Observe Medical is working with a network of leading distributors
to provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.
d in Oslo\, Norway.\
\
Further information is available at www.observemedical.com.\